{
    "root": "f3305f0b-fb9e-4009-b28f-47fe9b1b618b",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "NALTREXONE HYDROCHLORIDE",
    "value": "20250201",
    "ingredients": [
        {
            "name": "NALTREXONE HYDROCHLORIDE",
            "code": "Z6375YW9SF"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "CROSPOVIDONE, UNSPECIFIED",
            "code": "2S7830E561"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "POLYETHYLENE GLYCOL 400",
            "code": "B697894SGQ"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        }
    ],
    "indications": "naltrexone hydrochloride tablets indicated treatment alcohol dependence blockade effects exogenously administered opioids . naltrexone hydrochloride shown provide therapeutic benefit except part appropriate plan management addictions .",
    "contraindications": "reduce risk precipitated withdrawal patients dependent opioids , exacerbation preexisting subclinical withdrawal syndrome , opioid-dependent patients , including treated alcohol dependence , opioid-free ( including tramadol ) starting naltrexone hydrochloride treatment . opioid-free interval minimum 7 10 days recommended patients previously dependent short-acting opioids .",
    "warningsAndPrecautions": "naltrexone hydrochloride tablets , usp available follows : 50 mg : yellow , round , biconvex , film-coated tablets debossed “ 326 ” one side scored side . bottles 30 ’ s…………… . . ndc 82804-199-30 store 20° 25°c ( 68° 77°f ) ; excursions permitted 15° 30°c ( 59° 86°f ) [ usp controlled room temperature ] . dispense tight container .",
    "adverseReactions": "naltrexone hydrochloride contraindicated : 1. patients receiving opioid analgesics . 2.patients currently dependent opioids , including currently maintained opiate agonists [ e.g . , methadone ) partial agonists ( e.g . , buprenorphine ) . 3.patients acute opioid withdrawal ( ) . 4.any individual failed naloxone challenge test positive urine screen opioids . 5.any individual history sensitivity naltrexone hydrochloride components product . known cross-sensitivity naloxone phenanthrene containing opioids .",
    "indications_original": "Naltrexone hydrochloride tablets are indicated in the treatment of alcohol dependence and for the blockade of the effects of exogenously administered opioids.\n                  Naltrexone hydrochloride has not been shown to provide any therapeutic benefit except as part of an appropriate plan of management for the addictions.",
    "contraindications_original": "To reduce the risk of precipitated withdrawal in patients dependent on opioids, or exacerbation of a preexisting subclinical withdrawal syndrome, opioid-dependent patients, including those being treated for alcohol dependence, should be opioid-free (including tramadol) before starting naltrexone hydrochloride treatment. An opioid-free interval of a minimum of 7 to 10 days is recommended for patients previously dependent on short-acting opioids.",
    "warningsAndPrecautions_original": "Naltrexone Hydrochloride Tablets, USP are available as follows: 50 mg: Yellow, round, biconvex, film-coated tablets debossed with “326” on one side and scored on other side.\n                  Bottles of 30’s……………..NDC 82804-199-30\n                  \n                  Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° and 30°C (59° and 86°F) [see USP Controlled Room Temperature]. Dispense in a tight container.",
    "adverseReactions_original": "Naltrexone hydrochloride is contraindicated in:\n                  \n                     \n                        1.\n                        Patients receiving opioid analgesics.\n                     \n                     \n                        2.Patients currently dependent on opioids, including those currently maintained on opiate agonists [e.g., methadone) or partial agonists (e.g., buprenorphine).\n                     \n                        3.Patients in acute opioid withdrawal (see WARNINGS).\n                     \n                        4.Any individual who has failed the naloxone challenge test or who has a positive urine screen for opioids.\n                     \n                        5.Any individual with a history of sensitivity to naltrexone hydrochloride or any other components of this product. It is not known if there is any cross-sensitivity with naloxone or the phenanthrene containing opioids."
}